ZYLOX-TONBRDG.MED.TECH.H1 - Asset Resilience Ratio
ZYLOX-TONBRDG.MED.TECH.H1 (818) has an Asset Resilience Ratio of 32.89% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of ZYLOX-TONBRDG.MED.TECH.H1 to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how ZYLOX-TONBRDG.MED.TECH.H1's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is ZYLOX-TONBRDG.MED.TECH.H1's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down ZYLOX-TONBRDG.MED.TECH.H1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of ZYLOX-TONBRDG.MED.TECH.H1 for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.15 Billion | 32.89% |
| Total Liquid Assets | €1.15 Billion | 32.89% |
Asset Resilience Insights
- Very High Liquidity: ZYLOX-TONBRDG.MED.TECH.H1 maintains exceptional liquid asset reserves at 32.89% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ZYLOX-TONBRDG.MED.TECH.H1 Industry Peers by Asset Resilience Ratio
Compare ZYLOX-TONBRDG.MED.TECH.H1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236 |
Medical Devices | 25.01% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
Stratec SE
XETRA:SBS |
Medical Devices | 0.29% |
|
Eurobio Scientific SA
PA:ALERS |
Medical Devices | 10.52% |
Annual Asset Resilience Ratio for ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
The table below shows the annual Asset Resilience Ratio data for ZYLOX-TONBRDG.MED.TECH.H1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 25.05% | €864.78 Million ≈ $1.01 Billion |
€3.45 Billion ≈ $4.04 Billion |
+12.48pp |
| 2023-12-31 | 12.57% | €424.29 Million ≈ $496.04 Million |
€3.38 Billion ≈ $3.95 Billion |
-7.57pp |
| 2022-12-31 | 20.14% | €655.37 Million ≈ $766.20 Million |
€3.25 Billion ≈ $3.80 Billion |
-26.36pp |
| 2021-12-31 | 46.50% | €1.51 Billion ≈ $1.77 Billion |
€3.25 Billion ≈ $3.80 Billion |
-- |
About ZYLOX-TONBRDG.MED.TECH.H1
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People's Republic of China and internationally. It offers a neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracrania… Read more